Phexxi is a contraceptive drug owned by Evofem Inc. It contains Citric Acid, Lactic Acid, and Potassium Bitartrate as its active ingredients. The drug obtained market authorization on May 22, 2020, and is available in a vaginal gel dosage form.
The generic version of Phexxi might become available after 15 March, 2033. This is predicated on the last patent (US11439610) of Phexxi due to expire on the same date. Up until this date, no generic version can be legally produced in the United States.
Phexxi is primarily used for the prevention of pregnancy. Its active ingredients citric acid, lactic acid, and potassium bitartrate contribute to its effectiveness by creating a hostile environment for sperm thereby preventing fertilization.
Phexxi's protection is covered by 4 patents. The last patent (US11439610) is expected to expire on 15 March 2033, after which the Phexxi generic might become available. Below are the details of the patent: